Disc Medicine's Bitopertin Meets All Primary and Secondary Endpoints in Phase 3 EPP Trial
Bitget2026/10/19 11:13- Disc Medicine on Oct. 19, 2026, reported bitopertin met all primary and secondary endpoints in the Phase 3 APOLLO trial.
- Results in erythropoietic protoporphyria showed increased pain-free time in light, fewer phototoxic reactions and improved quality of life versus placebo.
- Bitopertin was generally well tolerated, with no new safety signals; dizziness was the most common treatment-related adverse event.
- An FDA application resubmission is planned by year-end 2026, with a decision anticipated by mid-2027.
- Topline results were announced; more detailed findings will be presented at a future medical conference.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
The AI arms race extends upstream! Reports say Intel, Nvidia, and AMD are prepaying over 100 billions NTD to secure advanced IC substrate production capacity.
NVIDIA, Intel, and AMD have collectively spent $5 billion in advance payments to aggressively secure high-end IC substrates from Taiwan. Driven by "big money for guaranteed orders," the top three Taiwanese substrate manufacturers have invested a record NT$161.2 billion to expand their production capacity. The tech giants' substantial financial commitments to secure supply chains highlight the intense competition and extreme scarcity of core AI materials.
Brent Crude Oil Hits $116 as Markets Weigh Another Inflation Shock
Crypto prices
More
